Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCRL2 | O00421 | 15/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.48 |
| ▸ | USP2 | O75604 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CCR2 | P41597 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027288 | 0.90 | CYP1A2 (0.61) | CCRL2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5029207 | 0.89 | CYP1A2 (0.60) | CCRL2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5027107 | 0.88 | CCRL2 (0.51) | CCRL2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5027259 | 0.88 | CCRL2 (0.53) | CCRL2 | |
| SCHEMBL5029495 | 0.87 | CYP1A2 (0.60) | CCRL2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5029067 | 0.87 | CCRL2 (0.51) | CCRL2CLK4 | |
| SCHEMBL5029621 | 0.85 | CCRL2 (0.52) | CCRL2CCR2KCNH2 | |
| SCHEMBL5033574 | 0.84 | CCRL2 (0.62) | CCRL2 | |
| SCHEMBL5033636 | 0.84 | CCRL2 (0.55) | CCRL2 | |
| SCHEMBL5029267 | 0.84 | CCRL2 (0.59) | CCRL2CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CCRL2 15/4885CYP1A2 2798/4885CYP3A4 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.